Palleon Pharmaceuticals is a biotechnology company focused on developing glycoimmune checkpoint inhibitors to treat cancer and autoimmune diseases. The company's core mission is to harness the power of glycobiology to create innovative immuno-oncology drugs and therapies. Based in Massachusetts, Palleon Pharmaceuticals aims to revolutionize cancer treatment through glycan editing, targeting the glycan structures on cell surfaces to modulate immune responses.
Palleon Pharmaceuticals has made significant strides in the field of immuno-oncology, leveraging advanced glycobiology techniques to develop novel therapeutic approaches. The company has attracted attention for its pioneering work in glycan editing, positioning itself as a leader in the next frontier of cancer treatment. Palleon's impact is underscored by its commitment to improving patient outcomes and advancing the science of immunotherapy.
